What are IDEXX's primary business segments and revenue drivers?

IDEXX operates through two main segments: the Companion Animal Group (CAG), which includes veterinary diagnostic products and services, pharmaceuticals, and information systems, and the Food and Environmental Division (FED), focused on water, dairy, and production animal testing. The CAG segment, particularly veterinary diagnostic products and services, is the largest contributor to revenue.

What is the company's strategy for future growth?

IDEXX's growth strategy involves developing and marketing new products with enhanced features, expanding market penetration, strengthening international sales efforts, pursuing new technology development and licensing, and completing strategic acquisitions. Key upcoming initiatives include the launch of the LaserCyte hematology system and continued development of veterinary pharmaceutical products.

What are the key risks and challenges facing IDEXX?

IDEXX faces intense competition, rapid technological changes, and significant government regulations in its operating markets. Supply chain dependencies on single-source suppliers for certain critical components and potential disruptions in international operations due to currency fluctuations and regulatory changes are also key risks.

What is the company's financial health and liquidity position?

As of December 31, 2001, IDEXX had $79.6 million in cash, cash equivalents, and short-term investments, and $164.2 million in working capital. Cash flow from operations was robust at $46.4 million. The company believes its current financial resources are sufficient to fund operations and future growth initiatives.

IDXX 10-K FY2001 Annual Report — Revenue, Net Income, EPS

Summary

IDEXX Laboratories, Inc. (IDXX) reported fiscal year 2001 results, showcasing revenue growth driven primarily by its Companion Animal Group (CAG) segment, which includes veterinary diagnostic products and services. The company continues to expand its product offerings, particularly in point-of-care diagnostics and veterinary pharmaceuticals, with recent FDA approval for its first drug, ACAREXX. While overall revenue increased, the company faces ongoing challenges including intense competition, rapid technological changes, and the complexities of global regulatory environments. IDEXX is actively managing its supply chain, particularly for key components of its diagnostic instruments, and is investing in research and development to fuel future growth, with notable upcoming product launches like the LaserCyte hematology system. The company's financial position remains solid, with sufficient liquidity to fund operations and strategic initiatives, and it continues to prioritize reinvestment in its business over dividend payments.

Key Highlights

1Revenue for the fiscal year 2001 reached $386.1 million, a 5.1% increase from $367.4 million in 2000, primarily driven by the Companion Animal Group (CAG).

2The Companion Animal Group (CAG) segment, representing the core veterinary business, saw revenue increase by 4% to $308.0 million in 2001.

3The Food and Environmental Division (FED) revenue grew by 9% to $78.0 million in 2001, boosted by water testing products and the acquisition of Genera Technologies Limited.

4IDEXX continues to invest in Research and Development, with R&D expenses at $28.4 million in 2001, consistent with previous years, focusing on new diagnostic platforms and pharmaceuticals.

5The company is preparing for the launch of the LaserCyte hematology system in the second half of 2002, a significant new product development in the hematology segment.

6No single customer accounted for 10% or more of sales in 2001 or 2000, indicating a diversified customer base.

7IDEXX reported net income of $37.6 million for 2001, a slight increase from $36.6 million in 2000, with diluted earnings per share of $1.09.

IDEXX LABORATORIES INC /DE Annual Report, Year Ended Dec 31, 2001

Summary

Key Highlights

Frequently Asked Questions